Bausch Health Companies Inc.
$22.19B- Market cap
- $2.45B
- Debt
- +$21.04B
- Cash
- −$1.31B
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.16x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt cap
Decision snapshot: BHC stock price at premium vs AI $6.56 current versus $4.02 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AI's multiple
Implied fair value · at BHC's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: BHC FY 2025 (ended Dec 31, 2025) · AI FY 2026 (ended Apr 30, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 10% equity / 90% debt · EV / Revenue 2.16x · EV / EBITDA 9.16x
Capital structure 46% equity / 54% debt · EV / EBITDA 1.09x
BHC carries the larger enterprise value at $22.19B against -$495.10M; AI trades on the lower EV / EBITDA multiple (1.09x vs 9.16x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Bausch Health Companies Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
C3.ai, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-37.98x
0.07x
Net debt / EBITDA
Leverage against operating earnings
8.15x
1.17x
Cash and equivalents
Liquid reserves on the balance sheet
$1.31B
$575.45M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AbbVie Inc.
BHC vs ABBV
Organon & Co.
BHC vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
BHC vs TEVA
SUPERNUS PHARMACEUTICALS, INC.
BHC vs SUPN
ANI PHARMACEUTICALS INC
BHC vs ANIP
ORACLE CORP
BHC vs ORCL
ServiceNow, Inc.
BHC vs NOW
Palantir Technologies Inc.
BHC vs PLTR
Snowflake Inc.
BHC vs SNOW
UiPath, Inc.
BHC vs PATH
PEGASYSTEMS INC
BHC vs PEGA
$21.04B
$43.74M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.